Suzanne Schindler, MD, PhD, Washington University School of Medicine in St. Louis, St. Louis, MO, comments on the evolution of biomarker testing in Alzheimer’s disease (AD). She highlights the shift from cerebrospinal fluid (CSF) biomarkers to blood tests, particularly the PrecivityAD and PrecivityAD2 tests. These blood tests have been used to identify patients suitable for anti-amyloid therapies, such as lecanemab, although CSF and amyloid positron emission tomography (PET) scans remain essential for confirmation in most cases. Prof. Schindler notes that increasing coverage by Medicare has widened the usage of amyloid PET scans. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2024 in Philadelphia, PA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
